Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding stufy to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy in moderate to severe Ulcerative Colitis CALDOSE-1.

Product: IMU-838 (vidofludimus calcium), a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH). Tablets with 5mg, 15mg and 22.5mg.

Sponsor: Immunic Therapeutics

Principal Investigator: Dr. William Holderman

We are looking for additional patients to participate in this study:

  • Moderate to severe Ulcerative Colitis diagnosed more than 3 months
  • Failure from previous treatment, had inadequate response to or lost response to, or was intolerant to immunomodulators or biologics, or corticosteroid dependent